GlassScriptPhysician profile
Christina Sherer
NPI 1477071629
$4,222.06
in general payments reported to CMS, 2019-2025
16 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $564 · 2024: $1,479 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,107 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,107.37 |
| Education | $114.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,169.35 | 2023-2025 | |
| Janssen Biotech, INC. | $676.06 | 2023-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $477.13 | 2023-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $400.46 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $317.68 | 2023-2025 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $283.51 | 2023-2025 | Entyvio |
| Gilead Sciences, INC. | $274.55 | 2023-2025 | Livdelzi |
| Madrigal Pharmaceuticals | $260.74 | 2025 | Rezdiffra |
| Genzyme Corporation | $108.13 | 2025 | |
| Aimmune Therapeutics, INC. | $64.22 | 2024 | |
| Celltrion USA INC. | $49.77 | 2024 | Zymfentra |
| Mylan Institutional INC. | $41.09 | 2023 | Hulio |
| Merck Sharp & Dohme LLC | $37.45 | 2023-2024 | Dificid |
| Qol Medical, LLC | $25.49 | 2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $20.07 | 2024 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $16.36 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christina Sherer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.